Table 3.
Clinical course after salvage surgery
| Characteristics | Cytotoxic agent (n = 12) | TKI (n = 16) | ICI (n = 4) | All drugs (n = 32) |
|---|---|---|---|---|
| Postoperative treatment | ||||
| Cytotoxic chemotherapy | 5 (42) | 1 (6) | 1 (25) | 7 (22) |
| Chemoradiotherapy/radiation therapy | 0 | 3 (19) | 0 | 3 (9) |
| TKI therapy | 1 (8) | 7 (44) | 0 | 8 (25) |
| Radiation therapy to the mediastinum | 2 (17) | 1 (6) | 0 | 3 (9) |
| Recurrence after salvage surgery | 8 (67) | 13 (81) | 2 (50) | 23 (72) |
| Initial metastatic/progressive site after surgery | ||||
| Locoregional | 0 | 4 (32) | 0 | 4 (13) |
| Distant | 8 (67) | 9 (56) | 2 (50) | 19 (59) |
| Treatment for recurrence after salvage surgery | ||||
| Systemic treatment | ||||
| Cytotoxic chemotherapy | 2 (17) | 2 (13) | 2 (50) | 6 (19) |
| Cytotoxic chemotherapy plus ICI therapy | 1 (8) | 0 | 0 | 1 (3) |
| ICI therapy | 2 (17) | 0 | 0 | 2 (6) |
| TKI therapy | 1 (8) | 5 (31) | 0 | 6 (19) |
| TKI plus cytotoxic chemotherapy | 1 (8) | 2 (13) | 0 | 3 (9) |
| Local treatment | ||||
| Radiation therapy | 4 (25) | 7 (44) | 0 | 11 (34) |
| Surgery for metastatic site | 2 (17) | 0 | 0 | 2 (6) |
Values are n (%). TKI tyrosine kinase inhibitor, ICI immune checkpoint inhibitor. Values are n (%) or median (range)